-
Oncolytics Biotech Inc. (NASDAQ:ONCY) Q1 2024 Earnings Call Transcript
10 May 2024 20:55 GMT
… trials, elements used in combination with chemotherapy drugs … cancer treatment space. Our conversations with potential pharmaceutical partners … cancer clinical trial with the FDA including the … pela in combination with gemcitabine and nab-paclitaxel. …
-
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
10 May 2024 20:48 GMT
… new frontiers in personalized medicine and, through innovative … .S. Food and Drug Administration (FDA) approved Yervoy 3 … and gemcitabine, is indicated as first-line treatment for … development and commercialization of pharmaceutical products. All statements …
-
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights
10 May 2024 10:32 GMT
… FDA on the design and objectives of a registrational trial … with atezolizumab and gemcitabine/nab-paclitaxel … treatments. Oncolytics is currently conducting and planning combination clinical trials … and development of pharmaceuticals, uncertainties related …
-
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
10 May 2024 05:18 GMT
… Medical Officer at PanCAN. "Increasing patient access to clinical trials … treatment groups:
Pelareorep in combination with atezolizumab, gemcitabine … a clinical-stage biotechnology company developing … development of pharmaceuticals, uncertainties related …
-
Health Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy
10 May 2024 05:18 GMT
… Phase 3 KEYNOTE-966 trial, which demonstrated a … 8 cycles and for gemcitabine, treatment could be continued beyond … the development of important medicines and vaccines. We aspire … fluctuations; the impact of pharmaceutical industry regulation and health …
-
AUA 2024: Back to Medical School: Immunology in NMIBC and Neoadjuvant MIBC for the Urologist
09 May 2024 14:29 GMT
… shared a slide featuring the FDA-approved agents in bladder cancer … . Currently, there are over 17 FDA-approved agents in bladder cancer … cells (Tregs)
Activating T cells: Gemcitabine enhances dendritic cell cross-presentation …
-
Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Radiotherapy, for Patients With Newly Diagnosed, High-Risk Endometrial Cancer After Surgery With Curative Intent
09 May 2024 11:00 GMT
… drug conjugate (ADC) being developed in collaboration with Kelun-Biotech, … s research efforts are trials focused on evaluating … with gemcitabine and cisplatin, is indicated for the treatment of … ; the impact of pharmaceutical industry regulation and health …
-
Most BCG-Unresponsive Bladder Cancer Responds to TAR-200 Treatment
08 May 2024 23:08 GMT
… SunRISe-1 clinical trial.
Data from the trial were recently … treatments. It is a targeted releasing system designed to deliver gemcitabine … (DOR; how long a drug keeps cancer under control) … of urology at SUNY Upstate Medical University Hospital in Syracuse, …
-
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
08 May 2024 13:00 GMT
… Serous Ovarian Cancer (IPROC) Drug Selection Committee (DSC) have … with cisplatin and gemcitabine for first-line treatment of adults … a novel class of medicines, ETBR inhibitors, to … ; Coherus’ expected initiating clinical trials for CHS-1000; Coherus’ …
-
Health Canada Approves KEYTRUDA® for Biliary Tract Carcinoma
10 May 2024 17:03 GMT
… , in combination with gemcitabine-based chemotherapy, for the treatment of adult patients … the Phase 3 KEYNOTE-966 trial, which demonstrated a statistically significant … , get special offers
from American Pharmaceutical Review – all delivered right to …